KRAS and non-small cell lung carcinoma: The Immunotarget registry recently demonstrated that ICIs may induce regression in some NSCLC tumors with actionable driver alterations, but clinical activity is significantly lower compared with the KRAS group, and the ALK group has a notable lack of response (44).